Design and structural optimization of novel 2H-benzo[h]chromene derivatives that target AcrB and reverse bacterial multidrug resistance.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Mar 2021
Historique:
received: 28 08 2020
revised: 21 10 2020
accepted: 23 11 2020
pubmed: 7 12 2020
medline: 1 5 2021
entrez: 6 12 2020
Statut: ppublish

Résumé

Drug efflux pumps have emerged as a new drug targets for the treatment of bacterial infections in view of its critical role in promoting multidrug resistance. Herein, novel chromanone and 2H-benzo[h]chromene derivatives were designed by means of integrated molecular design and structure-based pharmacophore modeling in an attempt to identify improved efflux pump inhibitors that target Escherichia coli AcrB. The compounds were tested for their efflux inhibitory activity, ability to inhibit efflux, and the effect on bacterial outer and inner membranes. Twenty-three novel structures were identified that synergized with antibacterials tested, inhibited Nile Red efflux, and acted specifically on the AcrB. Among them, WK2, WL7 and WL10 exhibiting broad-spectrum and high-efficiency efflux inhibitory activity were identified as potential ideal AcrB inhibitors. Molecular modeling further revealed that the strong π-π stacking interactions and hydrogen bond networks were the major contributors to tight binding of AcrB.

Identifiants

pubmed: 33279291
pii: S0223-5234(20)31021-7
doi: 10.1016/j.ejmech.2020.113049
pii:
doi:

Substances chimiques

AcrB protein, E coli 0
Anti-Bacterial Agents 0
Benzopyrans 0
Escherichia coli Proteins 0
Multidrug Resistance-Associated Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113049

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that this study was carried out only with public funding. There is no funding or no agreement with commercial for profit firms.

Auteurs

Yinhu Wang (Y)

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Wenhua Road, Jinan, 250012, China; School of Pharmacy, Liaocheng University, Liaocheng, China.

Rawaf Alenazy (R)

Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5000, Australia; Department of Medical Laboratory, College of Applied Medical Sciences-Shaqra, Shaqra University, 11961, Saudi Arabia.

Xinjie Gu (X)

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Wenhua Road, Jinan, 250012, China.

Steven W Polyak (SW)

Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5000, Australia.

Panpan Zhang (P)

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Wenhua Road, Jinan, 250012, China.

Matthew J Sykes (MJ)

Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5000, Australia.

Na Zhang (N)

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Wenhua Road, Jinan, 250012, China.

Henrietta Venter (H)

Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5000, Australia. Electronic address: rietie.venter@unisa.edu.au.

Shutao Ma (S)

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Wenhua Road, Jinan, 250012, China. Electronic address: mashutao@sdu.edu.cn.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
alpha-Synuclein Humans Animals Mice Lewy Body Disease

Classifications MeSH